This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Nicomide
- Generic Name
- Zinc glycinate
- DrugBank Accession Number
- DB14493
- Background
Glycoprotein marker of gastrointestinal cancer.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Zinc glycinate (DB14493)
- Weight
- Average: 213.5
Monoisotopic: 211.977549 - Chemical Formula
- C4H8N2O4Zn
- Synonyms
- Zinc bisglycinate
- Zinc(II) glycinate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbamazepine Zinc glycinate can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. Ceftibuten Zinc glycinate can cause a decrease in the absorption of Ceftibuten resulting in a reduced serum concentration and potentially a decrease in efficacy. Cephalexin Zinc glycinate can cause a decrease in the absorption of Cephalexin resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinoxacin Zinc glycinate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Ciprofloxacin Zinc glycinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Zinc cation ionic 13S1S8SF37 23713-49-7 PTFCDOFLOPIGGS-UHFFFAOYSA-N - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BumP DHA Zinc glycinate (15 1/1) + Cobamamide (500 mg/1) + Flavin adenine dinucleotide (1 mg/1) + Flavin mononucleotide (2 mg/1) + Iron (15 mg/1) + Leucovorin (1 mg/1) + Levomefolate magnesium (1 mg/1) + Magnesium oxide (125 mg/1) + NADH (25 ug/1) + Omega-3 fatty acids (300 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxal phosphate (5 mg/1) + Pyridoxine hydrochloride (20 mg/1) Capsule Oral Centurion Labs 2017-03-24 2017-04-17 US 
Folet DHA Zinc glycinate (10 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2700 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (12 ug/1) + D-alpha-Tocopherol acetate (18 [iU]/1) + Doconexent (350 mg/1) + Docusate sodium (50 mg/1) + Ferrous bisglycinate (38 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (40 mg/1) + Riboflavin (3.4 mg/1) + Selenium (65 ug/1) + Thiamine hydrochloride (3 mg/1) Capsule, liquid filled; Kit; Tablet Oral Pronova Corporation 2014-08-28 2017-03-15 US Nicomide Zinc glycinate (27 mg/1) + Chromium (100 ug/1) + Cupric oxide (2 mg/1) + Folic acid (500 ug/1) + Nicotinamide (750 mg/1) + Selenium (50 ug/1) Tablet Oral Avion Pharmaceuticals, Llc 2014-12-08 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 681VJX72FE
- CAS number
- 14281-83-5
- InChI Key
- UOXSXMSTSYWNMH-UHFFFAOYSA-L
- InChI
- InChI=1S/2C2H5NO2.Zn/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
- IUPAC Name
- zinc(2+) bis(2-aminoacetate)
- SMILES
- [Zn++].[H]N([H])CC([O-])=O.[H]N([H])CC([O-])=O
References
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Tablet, coated Oral Capsule, liquid filled; kit; tablet Oral Tablet Oral Kit Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 194.0 mg/mL ALOGPS logP -1.5 ALOGPS logP -3.4 Chemaxon logS -0.04 ALOGPS pKa (Strongest Acidic) 2.31 Chemaxon pKa (Strongest Basic) 9.24 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 66.15 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 26.84 m3·mol-1 Chemaxon Polarizability 6.25 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 09, 2018 19:48 / Updated at June 12, 2020 16:53